(Q34050677)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

HIV drug resistance and viral fitness (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

Clavel F

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Race E

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

41-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

RNA virus mutations and fitness for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

The not-so-great escape

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

The frequency of resistant mutant virus before antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

The accuracy of reverse transcriptase from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949023-X

7 January 2021

10.1016/S1054-3589(00)49023-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11013760%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference